Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rilonacept and canakinumab.

× No keyword cloud information.

3 in total

Review 1. Actual status of antiinterleukin-1 therapies in rheumatic diseases.

Authors: Matthias Geyer; Ulf Müller-Ladner
Journal: Curr Opin Rheumatol Date: 2010-05 Impact factor: 5.006

Review 2. Rilonacept--CAPS and beyond.

Authors: Neil Stahl; Allen Radin; Scott Mellis
Journal: Ann N Y Acad Sci Date: 2009-12 Impact factor: 5.691

3. Use of canakinumab in the cryopyrin-associated periodic syndrome.

Authors: Helen J Lachmann; Isabelle Kone-Paut; Jasmin B Kuemmerle-Deschner; Kieron S Leslie; Eric Hachulla; Pierre Quartier; Xavier Gitton; Albert Widmer; Neha Patel; Philip N Hawkins
Journal: N Engl J Med Date: 2009-06-04 Impact factor: 91.245

3 in total

15 in total

1. Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin.

Authors: Alexandra Taracanova; Irene Tsilioni; Pio Conti; Errol R Norwitz; Susan E Leeman; Theoharis C Theoharides
Journal: Proc Natl Acad Sci U S A Date: 2018-09-19 Impact factor: 11.205

2. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist.

Authors: Megha Garg; Adriana A de Jesus; Dawn Chapelle; Paul Dancey; Ronit Herzog; Rafael Rivas-Chacon; Theresa L Wampler Muskardin; Ann Reed; James C Reynolds; Raphaela Goldbach-Mansky; Gina A Montealegre Sanchez
Journal: JCI Insight Date: 2017-08-17

Rilonacept and canakinumab.

Review 1. Actual status of antiinterleukin-1 therapies in rheumatic diseases.

Review 2. Rilonacept--CAPS and beyond.

3. Use of canakinumab in the cryopyrin-associated periodic syndrome.

1. Substance P and IL-33 administered together stimulate a marked secretion of IL-1β from human mast cells, inhibited by methoxyluteolin.

2. Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist.

Review 3. Urticaria and Angioedema: an Update on Classification and Pathogenesis.

Review 4. Oxalate, inflammasome, and progression of kidney disease.

5. Development of Immunopathogenesis Strategies to Treat Behçet's Disease.

6. Anti-Interleukin-1 Agents in Adult Onset Still's Disease.

Review 7. NLR-Dependent Regulation of Inflammation in Multiple Sclerosis.

Review 8. Targeting the IGF-Axis for Cancer Therapy: Development and Validation of an IGF-Trap as a Potential Drug.

Review 9. The role of interleukin-1 in general pathology.

10. Canakinumab for refractory RA: a case report.